Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 1,177 shares, a growth of 97.5% from the May 14th total of 596 shares. Based on an average trading volume of 10,593 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG raised its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter. XY Capital Ltd grew its stake in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares during the last quarter. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the 2nd quarter worth approximately $391,000. Finally, Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000.

Ascentage Pharma Group International Stock Performance

Shares of NASDAQ AAPG traded up $0.23 during midday trading on Monday, hitting $17.83. 7,891 shares of the company’s stock were exchanged, compared to its average volume of 4,669. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. Ascentage Pharma Group International has a twelve month low of $16.92 and a twelve month high of $48.45. The firm’s fifty day simple moving average is $22.10 and its 200-day simple moving average is $24.70.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million during the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International will post -0.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AAPG has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, April 13th. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price for the company. Finally, Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.